The EAY191-N2 clinical study, Phase II Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense Mutation or Genomic Deletion in NF1, part of the ComboMATCH precision medicine initiative, is open for patients who have hormone receptor-positive (HR+) breast cancer with NF1 Nonsense or Frameshift mutation. Patients will be enrolled into two different cohorts. Cohort 1 is testing the combination of fulvestrant and binimetinib in HR+ patients who have never received fulvestrant (fulvestrant-naïve). Cohort 2 is assessing the addition of binimetinib to fulvestrant for patients who have previously received fulvestrant (fulvestrant-exposed) and their disease progressed.
Make America Healthy Again
President Trump released an Executive Order (EO) establishing the "Make America Healthy Again (MAHA) Commission,” Feb. 13 to be led by the new Department of Health and Human Services Secretary Robert F. Kennedy Jr.
Read moreScope of Practice Bills Introduced At State Legislative Level
The American College of Radiology® (ACR®) is tracking more than 58 scope of practice bills across 22 states with more expected to be considered.
Read moreACR Others Challenge MAC Position on Minimally Invasive Arthrodesis of the Sacroiliac Joint
The American College of Radiology® (ACR®) and other medical specialty societies that use or perform interventional pain and spine procedures told three of the seven Medicare Administrative Contractors (MACs) that implementation of a new policy as written could limit access to a safe, effective and durable treatment option, potentially exacerbating healthcare disparities among Medicare patients.
Read more